Israeli study finds that the Pfizer–BioNTech vaccine may be less effective against the South African variant when compared to other strains of the virus
An Israeli study finds that the Pfizer–BioNTech vaccine may be less effective against the South African variant when compared to other strains of the virus.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan to read this report and the complete Premium retrospective archive.
HealthIsraeli study finds that the Pfizer–BioNTech vaccine may be less effective against the South African variant when compared to other strains of the virus
View Premium plansBrowse free archive reportsAn Israeli study finds that the Pfizer–BioNTech vaccine may be less effective against the South African variant when compared to other strains of the virus.